A Phase 3 interventional study of Albendazole and Placebo in Toxocariasis, sponsored by Hospital de Niños R. Gutierrez de Buenos Aires. Active, not recruiting at 1 site in Argentina. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2023-03-02.
Sponsored by Hospital de Niños R. Gutierrez de Buenos Aires · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate effectiveness of albendazole in the treatment of the asymptomatic infection with the parasite Toxocara in children. Treatment response is defined as a reduction in the number of eosinophils in blood. The study drug will be compared to placebo and randomly assigned in a double blind manner. Follow up will be prospective. 50 children (25 per group) will be enrolled in the study.
52 studies on the registry are indexed under Eosinophilia; 9 are open to participants now.
This study's enrollment of 45 is close to the median of 48 across 32 interventional studies indexed under Eosinophilia.
Browse Eosinophilia studies →Hospital de Niños R. Gutierrez de Buenos Aires is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Albendazole 10 - 15 mg/kg/day BID for 15 days
Drug: Albendazole
Placebo BID for 15 days
Drug: Placebo
Albendazole 10 - 15 mg/kg/day BID for 15 days
Placebo BID for 15 days
Mean absolute reduction in eosinophil count from baseline
Time frame: 12 months after treatment
Reduction in eosinophil count in more than 60% from baseline
Time frame: 1 year
Incidence of adverse drug events
Time frame: 3, 6, 9 and 12 months after treatment
Mean absolute reduction in eosinophil count
Time frame: 3, 6, 9 months after treatment
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Sep 2008, a primary completion of Jul 2015 and a completion of Jul 2025. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albendazole
Hospital de Niños R. Gutierrez de Buenos Aires